Skip to main content
Medical Reference · Condition Monograph

AL amyloidosis

AL아밀로이드증

A disease in which abnormal proteins (amyloid) accumulate in organs and impair their function. Because it can involve multiple organs, including the heart, kidneys, and nerves, a diagnosis that accurately identifies the causative protein is important.

History

Amyloidosis is the collective term for diseases in which proteins in the body fail to maintain their normal shape and misfold, turning into poorly soluble fibers (amyloid fibrils) that accumulate in the spaces between organ tissues. The important point is that it is not "a single disease" but "a group of diseases caused by various causative proteins accumulating in a similar way." For this reason, the name of the disease alone does not sufficiently explain the cause, and the direction of treatment is determined only after confirming which protein formed the deposits.

The word "amyloid" originates from the name given by 19th-century pathologists who observed that deposits in organs looked like starch in the iodine reaction. It is now known that they are actually protein aggregates rather than starch, but the name has remained. As medicine later advanced, it was established that the deposits are made of proteins, take a fibrillar form under the microscope, and share a specific structure.

Advances in diagnostic technology are especially important in the history of amyloidosis. At one time, it was often discovered incidentally at autopsy or suspected only after advanced kidney failure or heart failure had developed. However, as Congo red staining and polarized light microscopy became standardized, it became possible to confirm relatively clearly "whether amyloid is actually present in the tissue."

Recent studies note that typing (type identification) techniques using laser microdissection and mass spectrometry have begun to be widely used to identify the type of protein in tissue more accurately. This change has direct significance for reducing diagnostic delays, avoiding inappropriate treatment, and connecting patients to subtype-specific targeted treatment at an earlier stage. The history of amyloidosis can be seen as a history of "changes in definition" and, at the same time, of "improvements in diagnostic accuracy."

Causes

The cause of amyloidosis can be explained by "which protein accumulated abnormally, for what reason, and for how long." Usually, if a protein 1) is produced in excessive amounts, 2) becomes structurally unstable, or 3) is not cleared from the body well, the molecules stick to one another over time and the deposits increase.

Representative forms of systemic amyloidosis include AL amyloidosis, caused by immunoglobulin light chains (AL); AA amyloidosis, caused by serum amyloid A (AA), an inflammatory response protein; and ATTR amyloidosis, caused by the transport protein transthyretin (ATTR). AL arises when plasma cells in the blood produce abnormal light chains, and AA can occur when inflammatory proteins remain elevated for a long time due to chronic inflammation, infection, autoimmune disease, and other conditions. For ATTR, a hereditary form with a genetic variant and a wild-type (age-related) form that occurs in older people without a genetic variant are known.

In addition, there is a form in which β2-microglobulin (Aβ2M) builds up and accumulates around the joints and bones in people receiving long-term hemodialysis, as well as forms that accumulate locally in only a specific organ. When the causative protein differs in this way, the organs involved, the rate of progression, and the treatment differ greatly. Recent studies emphasize that because treatment is completely different depending on the subtype, moving quickly from "suspected amyloidosis → subtype identification" is the most realistic approach to the cause.

Genetic Epidemiology

Genetic epidemiology deals with "in which populations and how often amyloidosis with genetic variants appears, and in what form it is expressed." The best-known hereditary form is hereditary transthyretin amyloidosis. If there is a variant in the transthyretin gene, the protein becomes unstable, and deposits can form in the peripheral nerves (numbness, sensory loss), the autonomic nerves (orthostatic hypotension, diarrhea and constipation), the heart (heart failure, arrhythmia), and elsewhere. Even with the same genetic variant, the age of onset, the organs involved, and the rate of progression differ from person to person, so it should also be remembered that "a family history is an important hint, but the absence of a family history does not completely rule it out."

Hereditary amyloidosis is classified as a rare disease, but in reality it is not uncommon for the diagnosis to be delayed and for it to be mistaken for another disease. For example, the possibility can be considered when unexplained neuropathy, recurrent carpal tunnel syndrome (hand numbness), or myocardial hypertrophy that is difficult to explain recurs within a family. Recent studies describe a trend in which, as access to genetic testing has improved, hereditary ATTR is being identified more often than before in patients with unexplained cardiomyopathy or neuropathy.

When a hereditary form is confirmed, "health planning for the whole family" must also be addressed. Family counseling, education about symptoms, and, where necessary, planning testing for family members are an important pillar of managing hereditary amyloidosis. Because the fact that "there is a genetic variant" can be a psychological burden, it is desirable to proceed with testing and counseling carefully while fully explaining the advantages and disadvantages.

The three representative genes associated with amyloidosis are as follows.

  1. TTR: hereditary transthyretin amyloidosis (ATTRv)
  2. FGA: hereditary fibrinogen Aα-chain amyloidosis (mainly kidney involvement)
  3. APOA1: apolipoprotein A-I-related hereditary amyloidosis

General Epidemiology

Amyloidosis is not a common disease overall, but it is "a disease that may be counted less often than it actually occurs because it is difficult to diagnose." Because symptoms such as fatigue, weight loss, swelling, and shortness of breath also appear in common diseases, it can take a long time before problems in several organs appear at the same time. In addition, time passes while the patient goes back and forth between several departments, such as cardiology, nephrology, and neurology, and is given a different explanation in each, so the diagnosis may be delayed.

Among the systemic amyloidoses, the subtypes that account for a clinically important share are AL, AA, and ATTR. AL commonly appears after middle age, and cardiac and renal involvement largely determine its prognosis. AA was formerly more common in regions with many chronic infections, but as treatment of inflammatory diseases has advanced, a decreasing trend has been observed in some regions. ATTR is attracting increasing attention, especially in the field of heart failure in older people.

In wild-type ATTR, musculoskeletal problems such as bilateral carpal tunnel syndrome, spinal stenosis, and biceps tendon rupture can appear before cardiac symptoms, and these clues can recur for years before leading to heart failure. Recent studies suggest that as noninvasive imaging tests and diagnostic algorithms have spread, some patients who were previously classified as having "myocardial hypertrophy of unknown cause" may be reclassified as having ATTR. In other words, the epidemiology of amyloidosis is influenced not only by "changes in the disease itself" but also by "changes in the ability to detect it."

Pathogenesis

Pathogenesis addresses "why proteins become amyloid and why organs are damaged." Proteins must originally fold into a precise shape to function. However, when factors such as genetic variants, overproduction due to inflammation, decline in quality control due to aging, and impaired clearance are present, some of the proteins misfold and stick to one another to form small aggregates. These aggregates gradually grow into long, rigid fibers (fibrils) and accumulate in the spaces between organ tissues.

Amyloid fibrils are characteristically rigid and poorly degraded, so they tend to accumulate. As accumulation progresses, organs are damaged in two ways. First, the deposits take up space, the tissue becomes stiff, and the normal structure breaks down. In the heart, the heart "stiffens" so that blood cannot fill it well, resulting in restrictive cardiomyopathy, and problems with electrical signal conduction can also arise. In the kidneys, the filtration apparatus is damaged so that proteinuria develops, and with progression it can lead to kidney failure. Second, the protein aggregates themselves can disrupt the environment around cells and invade the microvessels, interfering with the supply of oxygen and nutrients.

Recent studies introduce discussion that aggregates at "the stage before they fully harden into fibrils" may be more toxic. This view also influences treatment strategy. In other words, not only "treatments that remove" what has already accumulated but also "treatments that slow the misfolding process itself," by reducing the precursor protein or stabilizing the protein in the early stage when accumulation begins, become important. Because the place where the precursor protein is produced (e.g., the liver, the bone marrow) differs by subtype, understanding the pathogenesis also naturally explains why the treatment targets differ.

Symptoms

The symptoms of amyloidosis differ by organ and may look similar to common diseases in the early stage. Therefore, it should be suspected more when "several seemingly unrelated symptoms appear together" rather than "a single symptom." Systemic symptoms may include fatigue, loss of appetite, and weight loss. With kidney involvement, foamy urine (proteinuria) and swelling are common, and if the swelling persists, it may appear as sudden weight gain, ankle swelling in the evening, and facial swelling in the morning.

With cardiac involvement, heart failure symptoms such as shortness of breath, difficulty breathing with exertion, and leg swelling can appear. It may also present as shortness of breath when lying down at night, leading a person to raise their pillow, or as becoming easily exhausted even with light activity. Symptoms related to arrhythmia or conduction disorders, such as dizziness, fainting, and palpitations, are also possible. If the nerves are involved, peripheral neuropathy such as numbness, sensory loss, and burning in the hands and feet can develop, and if the autonomic nerves are involved, orthostatic hypotension and gastrointestinal symptoms such as diarrhea, constipation, and early satiety can appear.

There are also symptoms that are relatively characteristic of each subtype. In AL, macroglossia, in which the tongue becomes enlarged, and bruising around the eyes (periorbital purpura) can be clues. In ATTR (especially wild-type), musculoskeletal symptoms such as bilateral carpal tunnel syndrome or spinal stenosis may appear first and then lead to cardiac symptoms. Recent studies explain that thinking about these "preceding symptoms" systematically as a group allows the diagnosis to be approached at an earlier stage.

Signs

Signs are the objective clues confirmed on examination or testing. With kidney involvement, proteinuria or albuminuria is confirmed on urinalysis, albumin is low on blood tests, and noticeable swelling may accompany these findings. Suspicion rises when severe swelling cannot be explained by liver disease or heart failure alone, or when there is heavy proteinuria but the course of diabetes is short or other complications do not fit well.

With cardiac involvement, a restrictive pattern may be observed on echocardiography, in which the heart walls appear thickened while systolic function is relatively preserved in the early stage. On electrocardiography, the electrical signals may appear weak, or conduction disorders may accompany it. If cardiac markers (such as BNP / NT-proBNP) are elevated on blood tests, it is a clue that cardiac stress is high. With liver involvement, the liver may be enlarged or liver enzymes may be elevated, and with skin or blood vessel involvement, easy bruising or a bleeding tendency may be seen. Macroglossia and periorbital purpura seen in AL are known as relatively characteristic physical findings.

Above all, the most important sign is the "multiorgan pattern." For example, the possibility of amyloidosis increases when signs that are difficult to explain with a single diagnosis are grouped together, such as when heart failure and proteinuria are present together, when myocardial hypertrophy and bilateral carpal tunnel syndrome are present together, or when neuropathy is accompanied by orthostatic hypotension. Recent studies emphasize that how quickly clinicians recognize such patterns is the key to reducing diagnostic delays.

Screening

Amyloidosis is not a disease for which large-scale screening of the general population has been standardized. Instead, "screening that picks out people in whom it should be suspected" is important. The goals of screening are, first, not to miss the possibility of amyloidosis and, second, to identify AL, whose treatment strategy is completely different, as quickly as possible.

Situations in which screening is especially needed are as follows. 1) When there is myocardial hypertrophy or heart failure that is difficult to explain, accompanied by clues such as bilateral carpal tunnel syndrome, spinal stenosis, or autonomic abnormalities. 2) When proteinuria is pronounced but is not well explained by common causes alone. 3) When peripheral neuropathy and orthostatic hypotension are present together. 4) When there are relatively characteristic findings such as macroglossia or periorbital purpura.

Another key element is screening for AL. Serum and urine protein electrophoresis and immunofixation, and the serum free light chain (FLC) test, are important for gauging "whether AL is possible" at a relatively early stage. Recent studies explain that for cardiac ATTR, a noninvasive diagnostic approach has become possible with a specific nuclear medicine test, so the process of screening for "patients who should undergo that test" has become more important. Screening is not simply listing a few tests but a process of clinical judgment that decides which tests to move forward for which combinations of clues.

Diagnosis

Diagnosis can be organized into three steps: 1) confirming whether amyloid is actually present, 2) identifying which protein it is made of (subtype), and 3) assessing which organs are involved and to what extent. The standard for the first step, "confirming presence," is biopsy. Relatively less invasive options include specimens from abdominal fat aspiration (fat pad biopsy), the lip or salivary glands, the rectal mucosa, the bone marrow, and other sites, and if necessary, tissue is obtained directly from an organ suspected of being involved (kidney, heart, and others). Amyloid deposition is confirmed when the tissue is stained with Congo red and the characteristic color change is seen under polarized light microscopy.

The second step, "subtype identification," is the key to treatment decisions. Specific proteins may be identified with immunostaining, but recent studies present protein identification using mass spectrometry after laser microdissection as an important method because it is more accurate. In particular, because major subtypes such as AL and ATTR have completely different treatments, starting treatment while the subtype is uncertain can be dangerous. The third step, assessment of organ involvement, combines organ-specific tests of the heart, kidneys, nerves, liver, and others. For the heart, echocardiography, cardiac MRI, specific nuclear medicine tests, and others can be used, and for the kidneys, urine and blood tests and, if necessary, kidney biopsy are considered.

Another major principle is that AL must always be excluded or confirmed. Because AL can be associated with plasma cell abnormalities in the blood, its treatment is urgent and the choice of drugs is completely different. For this reason, monoclonal protein evaluation and the serum free light chain test cannot be left out of the diagnostic process. Diagnosis is not "a single test" but a process that completes confirmation of presence + subtype identification + assessment of organ involvement together.

Treatment

Treatment combines "treatment that reduces or stabilizes the causative protein so that it no longer accumulates" with "supportive treatment that preserves the function of organs that are already damaged." Because the direction of treatment differs greatly by subtype, subtype identification is essential before treatment. In AL amyloidosis, the key is to suppress the plasma cells and reduce light chain production. Chemotherapy is central, and in some patients autologous hematopoietic stem cell transplantation is considered. Recent studies summarize a trend in which response rates and prognosis are improving as combination regimens including daratumumab have become widely used.

For AA amyloidosis, treatment is "not letting inflammation drag on." Strongly controlling the underlying disease (rheumatic disease, autoinflammatory disease, chronic infection, and others) to lower the concentration of inflammatory proteins can slow or stabilize the progression of deposition. For ATTR amyloidosis, the key treatments are drugs that stabilize the protein (e.g., tafamidis) and treatments that reduce the production of the precursor protein made in the liver (RNA-based therapies and others). Recent studies explain that options are increasing, with even gene-editing approaches being explored clinically.

For any subtype, supportive treatments such as those for heart failure (adjusting diuretics, managing arrhythmias), kidney failure (salt control, dialysis), hypotension (education on postural changes, medication), and nutritional problems are very important for patients' quality of life and survival. In advanced cases, dialysis or organ transplantation may be considered, and here too the decision depends on the subtype and overall condition. The key to treatment is to confirm the subtype first and to carry out treatment that reduces the causative protein together with organ-protective treatment.

Prognosis

The prognosis depends greatly on the subtype, the organs involved, and the timing of the start of treatment. In particular, whether the heart is involved often determines the overall prognosis, so when heart failure symptoms such as shortness of breath and swelling are present, more rapid evaluation is needed. In systemic amyloidosis, "which organs have lost how much function" is more directly connected to the actual prognosis than "how much has accumulated."

AL amyloidosis can progress rapidly if untreated, but if treatment that rapidly suppresses light chain production is started right after diagnosis and a good response is obtained, organ function can recover and survival can improve greatly. For this reason, "diagnostic delay" is cited as a representative factor that worsens the prognosis. ATTR amyloidosis often progresses relatively slowly, and in wild-type ATTR in particular, a pattern of worsening over several years is common. In AA amyloidosis, progression can slow or stabilize if the underlying inflammation is well controlled, but if the inflammation persists, deposits continue to increase and can lead to decline in kidney function and other problems.

The common principle that determines prognosis is "whether the subtype is identified quickly and treatment is started before organ damage becomes severe." From a layperson's point of view, this means that promptly suspecting "a rare disease for which treatment differs" when unexplained heart failure, proteinuria, and neuropathy overlap can be directly connected to actual survival. Recent studies summarize a trend in which, as treatment strategies have advanced, survival has become longer than in the past and the proportion of patients achieving organ responses has increased.

Prevention

The concept of prevention for amyloidosis differs by subtype. There are forms for which complete primary prevention (preventing onset itself) is possible, and forms for which secondary prevention (reducing organ damage through early detection and early treatment) is realistically central. AA amyloidosis has a relatively clear prevention strategy. Consistently controlling chronic inflammatory diseases (rheumatic diseases, inflammatory bowel disease, autoinflammatory diseases, and others) and appropriately treating chronic infections so that inflammatory proteins do not remain elevated for long periods can lower the risk of developing it. In other words, "not leaving inflammation unaddressed for a long time" is itself prevention.

AL amyloidosis is difficult to prevent directly through lifestyle alone. However, when there are "warning signs" such as unexplained proteinuria, unexplained heart failure, or neuropathy, performing monoclonal protein and serum free light chain testing early to reduce diagnostic delay is realistic prevention (early detection). This early detection is important in that it ensures that the "timing" at which treatment is possible is not missed.

For hereditary ATTR, prevention by eliminating the genetic variant is difficult, but when there is a family history or a genetic variant has been confirmed, an approach that reduces organ damage through early detection and early treatment, with regular follow-up and education about symptoms, is important. Complete prevention is also difficult for age-related forms such as wild-type ATTR, but appropriate differential diagnosis and connection to treatment in older patients with heart failure can play a preventive role by reducing complications and worsening.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.